Second primary cancers alter radiotherapy plans in 37% of affected head and neck patients

Among 285 head and neck cancer patients, 28.4% had another primary cancer, leading to treatment modifications in 37% of affected patients.

KEY POINTS

  • This retrospective cohort study from the Limburg Oncological Centre, Belgium, analyzed 285 patients with newly diagnosed head and neck cancer referred for curative-intent radiotherapy between 2022 and 2024. Eighty-one patients (28.4%) had a synchronous malignancy, a previously treated malignancy, or both. Specifically, 24/285 (8.4%) had synchronous disease, 47/285 (16.5%) had a previous primary cancer, and 10/285 (3.5%) had both.
  • A second primary cancer affected the planned head and neck treatment in 30/81 patients (37.0%). Among those with another malignancy, treatment modifications included radiotherapy field adaptation in 19 (23.5%), a delay exceeding six weeks after diagnosis in 11 (13.6%), changes to chemotherapy in two (2.5%), altered RT fractionation in two (2.5%), and conversion to palliative treatment in one (1.2%). Five patients experienced more than one modification, so the categories were not mutually exclusive.
  • Changes to radiation fields were the most frequent consequence. Prior irradiation required field modification in four patients (4.9%), including exclusion of previously treated nodal regions or dose reduction to protect cumulative OAR exposure. Another 14 patients (17.3%) underwent concurrent irradiation of a synchronous malignancy using coordinated treatment plans. One case involved unavoidable overlap between treatment fields, illustrating the challenges of delivering curative treatment for multiple cancers.
  • Treatment delays were often related to additional diagnostic evaluation or treatment of the second malignancy. Among the 81 affected patients, four (4.9%) experienced delays because further imaging or biopsy was necessary, six (7.4%) because of treatment of the second primary, and one because of postoperative recovery. The study defined a clinically relevant treatment delay as initiation of head and neck RT more than six weeks after cancer diagnosis, rather than directly measuring the effect of delay on tumor control.
  • Some patients required changes in systemic treatment or fractionation. Two patients received weekly cisplatin instead of the planned chemotherapy schedule to accommodate concurrent treatment, while two received a hypofractionated Christie regimen because of multiple synchronous cancers and reduced general fitness. One patient with painful oropharyngeal cancer and synchronous small cell lung cancer received 20 Gy in five fractions before systemic chemoimmunotherapy, representing a change from the originally intended curative approach.
  • The additional malignancies were frequently identified during routine staging or surveillance. Among the 81 patients, 32 (39.5%) had the second primary identified during staging, while seven (8.6%) were identified during surveillance of another malignancy. At head and neck RT planning, 26 patients (32.1%) were receiving active treatment for their second cancer, while 46 (56.8%) were under surveillance after previous curative treatment.
  • The analysis describes treatment complexity rather than the oncological consequences of modifications. Radiotherapy changes were classified retrospectively by one reviewer, and outcomes such as local control, survival, treatment interruption, and toxicity were not compared. The proportion of patients with second primaries reflects a selected referral population and includes previous cancer history, rather than representing the incidence of new second cancers after head and neck treatment.

CLINICAL TAKEAWAY

Synchronous and previously treated malignancies frequently complicate curative-intent head and neck radiotherapy, particularly through target-volume changes, previous-dose overlap, and treatment delays. These findings support comprehensive staging, access to previous RT plans, and coordinated multidisciplinary decision-making before simulation. However, the study does not establish whether the observed treatment adaptations improve or compromise oncological outcomes.

SOURCE

Cancers

Browse more research Suggest a correction